【News】Cyfuse is approved for listing on the Tokyo Stock Exchange


Cyfuse Biomedical K.K. (Minato-ku, Tokyo; CEO: Shizuka Akieda, from now on referred to as “Cyfuse”), a company that develops innovative regenerative medical technology, was approved to be listed on Tokyo Stock Exchange Growth on October 27, 2022.
 Cyfuse is a company invested by CYBERDYNE Inc. Cyfuse is scheduled to be listed on December 1, 2022, and its ticker code will be 4892.

About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. is a regenerative medicine venture company that aims to contribute to society by delivering three-dimensional tissues and organs created solely from cells as new “3D cell products” (*1) as a new treatment option to the field of regenerative medicine, drug discovery, and other advanced medical fields.

(1)In the regenerative medicine area, the development of a pipeline toward approval of regenerative medicine products and contracted research cell products.
(2)In the drug discovery support area, the development of cell products as tools for drug discovery support with pharmaceutical companies.
(3)In the device area, development and sales of three-dimensional cell stacking system devices (bio 3D printers and consumables) equipped with basic technology, application of technology, and development of new technology for cell product development.

(*1) 3D cellular products
A generic term for “cellular products” produced from human cells, such as tissues and organs as regenerative medical products and 3D tissue and cellular structures used in research and development.

Based on its business strategy, Cyfuse is developing its business in multiple areas with its unique 3D cell products, which are created based on its fundamental technologies. About regenerative medicine products, which will be a future earnings driver, Cyfuse is currently conducting clinical development of its main pipeline products for peripheral nerve regeneration, bone and cartilage regeneration, and vascular regeneration to obtain approval for regenerative medicine products. Of these, Cyfuse is currently conducting investigator-initiated clinical trials for a regenerative medicine product for peripheral nerve regeneration (development code: CYF-PA1), and plans to start company clinical trials in 2023, file for approval in 2025, and obtain approval in 2026.
Cyfuse has developed a three-dimensional cell lamination technology (fundamental technology) that enables the creation of three-dimensional tissues and organs using only cells without artificial scaffold materials and a cell-based 3D printer (bio 3D printer) that incorporates this fundamental technology. In the future, through business expansion, Cyfuse aims to expand this Japan-originated technology globally and become a key player in regenerative and cellular medicine.

Cyfuse release (Available in Japanese only):

■Japan Exchange Group “Information on Newly Listed Companies” website